- Home
- Pathology Industry
- Amgen Market and Forecasts, May 2012
Industries
- Pathology (62)
- Drug Discovery and Development (42)
- Drug and Medication (41)
- Business Services (32)
- Biopharmaceutical (15)
-
- Metal and Mineral (13)
- Pharmaceutical (12)
- Biological Therapy (11)
- Electronic Manufacturing (9)
- Investment Banking (7)
- Oil and Gas Energy (6)
- Biotechnology (5)
- Chemical and Material (5)
- Genomics (5)
- Healthcare (4)
- Pension (4)
- Banking (3)
- Drug Delivery Technology (3)
- Education and Training (3)
- Electronic Component and Semiconductor (3)
Top countries
Publication dates
All regions
Amgen Market and Forecasts, May 2012
You might be interested in: clinical trial, cancer, drug, more »
industry reports
Amgen Inc. - Company Report for Year 2011
- Company report
- April 2011
- 184 pages
... Communicate, and be accountable amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, amgen was one of the first companies to realize ...
- Industries: Pathology
- Countries: United States
Amgen Inc. - Investment Analysis, July 2011
- Company report
- July 2011
- 10 pages
... In unit demand. This sales decrease reflects an overall decline in the segment largely offset by an increase in share and expansion home media press releases press release detail amgen - media - press ...
- Industries: Pathology
- Countries: United States
Company Report: Pharmaceutical in The United States for Year 2011
- Company report
- January 2011
- 3 pages
... Filings that the lawsuits Allege that amgen engaged in a wide variety of illegal marketing practices. The federal investigations, according to amgen, seem to involve marketing, pricing and dosing ...
- Industries: Pharmaceutical
- Countries: United States
Investor presentation: Medicine in The United States for Year 2011
- Company report
- March 2011
- 13 pages
... To update. amgen is a leader in the manufacturing of biotechnology medicines 8 provided may 8, 2012 as part of an oral presentation and is qualified by such, contains forward-looking statements, actual ...
- Industries: Drug and Medication
- Countries: United States
Medical Technology Stock Letter - Investment Analysis, February 2011
- Company report
- February 2011
- 8 pages
... amgen buys-in to the oncology game except to the extent that everyone remains hung up on the soap opera that is obesity drug development, the big news from the last few weeks was amgen S acquisition ...
- Industries: Pathology
- Countries: United States, Egypt
Company Report: Drug and Medication in The United States for Year 2011
- Company report
- March 2011
- 25 pages
- by Research Paper
... Teva is seeking declaratory relief and damages in an unspecified amount. Pursuant to the company's license agreement with amgen, so long as a patent infringement proceeding by a third party against ...
- Industries: Drug and Medication
- Countries: United States
Reliance Industries Ltd. - Company Report for Year 2012
- Company report
- January 2012
- 4 pages
... To gain an experimental leukemia drug. Options: a. Celgene drug b. B b biotech c. Dechert d. amgen answer: amgen inc., The world's largest biotechnology company, agreed to buy micromet ...
- Countries: India
Company Report: Home and Office Goods in The United States for Year 2011
- Company report
- January 2011
- 8 pages
... With rationale for a different company (amgen). (This is the conclusion) amgen S roe is much higher than the industry average, showing that this company provides a higher return on investment to its ...
- Industries: Home and Office Goods
- Countries: United States
Company Report: Pathology in The United States and Australia for Year 2012
- Company report
- April 2012
- 4 pages
... Tumoural injection. However, unlike viralytics single arm trial phase ii, amgen's phase iii trial is a randomised, controlled trial with the control arm using gm-csf as a comparator. Gm-scf can be used as a control ...
- Industries: Pathology
- Countries: United States, Australia
Cytokinetics Inc. - Company Report for Year 2011
- Company report
- December 2011
- 341 pages
... And scope of clinical trials and development activities for our drug cands and potential drug cands conducted by ourselves or our partners, such as amgen inc., Including the anticipated timing ...
- Industries: Drug Discovery and Development
- Countries: United States
Reportlinker.com © Copyright 2012. All rights reserved
